Date: 2014-10-30
Type of information: Production agreement
Compound: undisclosed biologic medicine
Company: BMS (USA - NY) Lonza (Switzerland)
Therapeutic area: undisclosed
Type agreement: production manufacturing
Action mechanism:
Disease: undisclosed
Details: * On October 30, 2014, BMS and Lonza announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza\'s mammalian manufacturing facility in Portsmouth, New Hampshire.
Financial terms: Financial terms were not disclosed.
Latest news:
